

MEET THE GUEST EDITOR

Douglas S. Krafte

Biology & Scientific Affairs
Icagen Inc.
P.O. Box 14487
Research Triangle Park
NC 27709
USA
E-mail: DKRAFTE@icagen.com

Dr. Douglas Krafte received his Bachelor's degree in molecular biology from Vanderbilt University, his Ph.D. in physiology from the University of Rochester and post-doctoral training in molecular neurobiology at Caltech. He held positions at Sterling-Winthrop and Boehringer Ingelheim before joining Aurora Biosciences as Group Leader for ion channel research. Dr. Krafte is currently Vice President, Biology, at Icagen and has held that position since 2002. From 1997-1999, he was the company's Director of Biology. His career has focused on ion channels and drug discovery for the past 18 years in a number of therapeutic areas including cardiovascular, CNS and autoimmune/inflammatory diseases.

SELECTED PUBLICATIONS

- [1] Kort, M.E.; Drizin, I.; Gregg, R.J.; Scanio, M.J.; Shi, L.; Gross, M.F.; Atkinson, R.N.; Johnson, M.S.; Pacofsky, G.J.; Thomas, J.B.; Carroll, W.A.; Krambis, M.J.; Liu, D.; Shieh, C.C.; Zhang, X.; Hernandez, G.; Mikusa, J.P.; Zhong, C.; Joshi, S.; Honore, P.; Roeloffs, R.; Marsh, K.C.; Murray, B.P.; Liu, J.; Werness, S.; Faltynek, C.R.; **Krafte, D.S.**; Jarvis, M.F.; Chapman, M.L.; Marron, B.E. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. *J. Med. Chem.*, **2008**, *51*, 407-16.
- [2] **Krafte, D.S.**; Bannon, A.W. Sodium channels and nociception: recent concepts and therapeutic opportunities. *Curr. Opin. Pharmacol.*, **2008**, *8*, 50-6.
- [3] Jarvis, M.F.; Honore, P.; Shieh, C.C.; Chapman, M.; Joshi, S.; Zhang, X.F.; Kort, M.; Carroll, W.; Marron, B.; Atkinson, R.; Thomas, J.; Liu, D.; Krambis, M.; Liu, Y.; McGaraughty, S.; Chu, K.; Roeloffs, R.; Zhong, C.; Mikusa, J.P.; Hernandez, G.; Gauvin, D.; Wade, C.; Zhu, C.; Pai, M.; Scanio, M.; Shi, L.; Drizin, I.; Gregg, R.; Matulenko, M.; Hakeem, A.; Gross, M.; Johnson, M.; Marsh, K.; Wagoner, P.K.; Sullivan, J.P.; Faltynek, C.R.; **Krafte, D.S.** A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc. Natl. Acad. Sci. USA.*, **2007** *104*, 8520-5.
- [4] Joshi, S.K.; Mikusa, J.P.; Hernandez, G.; Baker, S.; Shieh, C.C.; Neelands, T.; Zhang, X.F.; Niforatos, W.; Kage, K.; Han, P.; **Krafte, D.S.**; Faltynek, C.; Sullivan, J.P.; Jarvis, M.F.; Honore, P. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. *Pain*, **2006**, *123*, 75-82
- [5] Zou, A.; Lin, Z.; Humble, M.; Creech, C.D.; Wagoner, P.K.; **Krafte, D.S.**; Jegla, T.J.; Wickenden, A.D. Distribution and functional properties of human KCNH8 (Elk1) potassium channels. *Am. J. Physiol. Cell Physiol.*, **2003**, *285*, C1356-66
- [6] Liu, Y.; Liu, D.; **Krafte, D.S.** Decrease of inward rectification as a mechanism for arachidonic acid-induced potentiation of hKir2.3. *Eur. Biophys. J.*, **2002**, *31*, 497-503.
- [7] Liu, Y.; Liu, D.; Printzenhoff, D.; Coghlan, M.J.; Harris, R.; **Krafte, D.S.** Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K⁺ channel hKir2.3. *Eur. J. Pharmacol.*, **2002**, *435*, 153-60.